Recent investigations into retatrutide, a dual activator for GLP-1 and GIP receptors, are demonstrating promising outcomes in managing excess mass and type 2 disease. Initial evidence suggest a distinct action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/